Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer
April 25, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., April 25, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn's Disease
April 24, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., April 24, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences to Present at the 19th Annual Future Leaders in the Biotech Industry Conference
April 12, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., April 12, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
March 29, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 29, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences Signs Collaboration Agreement With Dr. Falk Pharma and OvaMed for the Development of TSO for Crohn's Disease
March 22, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences to Report Fourth Quarter and Full Year 2011 Financial Results
March 20, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 20, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences to Host Analyst & Investor Event in New York City
March 13, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 13, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences to Present at the 24th Annual ROTH Conference
March 08, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 8, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences to Present at the Cowen and Co. 32nd Annual Health Care Conference
March 01, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 1, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences Announces Phase 1 Clinical Trial Results for TSO in Crohn's Disease
February 28, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...